About us

We push the boundaries of science to deliver life changing medicines

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

We operate in more than 100 countries and our innovative medicines are used by millions of patients worldwide. We want to be valued as a source of great medicines and trusted as a company that delivers business success responsibly. We are committed to operating with integrity and high ethical standards across all our activities.

We push the boundaries of science to deliver life-changing medicines.

Our proposition to investors

You may also be interested in

Delivering great medicines to patients through innovative science

We are focused on delivering innovation and growth through our science-led, innovation strategy that is underpinned by a broad R&D platform focused on three core therapeutic areas, a balanced portfolio of specialty and primary care products and a strong global commercial presence, with strength in the emerging markets.

Read more

Senior Executive Team

Our Senior Executive Team led by Pascal Soriot, Chief Executive Officer, is responsible for business operations and company development, regularly reviewing and deciding all major business issues. Read more

Key facts

Read more

The quality of transformation we are seeing across all core areas of our business further underpins our confidence in AstraZeneca's longer term prospects.